---
document_datetime: 2025-09-04 11:37:25
document_pages: 18
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/gazyvaro-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: gazyvaro-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 9.4429844
conversion_datetime: 2025-12-26 09:53:21.362185
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Gazyvaro

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| II/0059              | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 28/11/2024                          | n/a                                         |                                  |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| PSUSA/10279 /202310   | Periodic Safety Update EU Single assessment - obinutuzumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 27/06/2024   | 06/09/2024   | SmPC and PL   | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10279/202310.   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|----------------------------------------------------------------------------------------------------------------------------------------------|
| II/0054/G             | This was an application for a group of variations. Grouped application comprising two variations as follows: C.I.4 - Update of section 4.8 of the SmPC in order to add cytokine release syndrome (CRS) to the list of adverse drug reactions (ADRs) with frequency rare, based on the cumulative review of the MAH safety database, clinical trials and literature. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 10.3. A.6 - To change the ATC Code of Obinutuzumab from L01XC15 to L01FA03. A.6 - Administrative change - Change in ATC Code/ATC Vet Code C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 05/09/2024   |              | SmPC and PL   | Not applicable.                                                                                                                              |
| IB/0055               | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 14/12/2023   | n/a          |               |                                                                                                                                              |
| IA/0057/G             | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 06/12/2023   | n/a          |               |                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |             |                                                                                                                      |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------|
| IA/0056   | B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 06/12/2023 | n/a        |             |                                                                                                                      |
| II/0053/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure | 07/09/2023 | 06/09/2024 | Annex II    |                                                                                                                      |
| II/0051   | Update of section 4.8 of the SmPC in line with the SmPC Guideline following the recommendation by PRAC in the outcome for the signal assessment of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 01/09/2022 | 05/05/2023 | SmPC and PL | SmPC new text The tabulated list of ADRs is updated to reflect: Infections and infestations Hepatitis B reactivation |

<div style=\"page-break-after: always\"></div>

|         | non-overt disseminated intravascular coagulation (DIC) (EPITT no: 19711). The Package Leaflet is updated accordingly. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |      | frequency Uncommon Nervous system disorders: Progressive multifocal leukoencephalopathy frequency Not known Gastrointestinal disorders: gastrointestinal perforation frequency Common For more information, please refer to the Summary of Product Characteristics.   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0050 | B.I.e.1.a - Introduction of a new design space or extension of an approved design space for the AS - One unit operation in the manufacturing process of the AS including the resulting IPCs and/or test procedures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 01/09/2022 | n/a        |      |                                                                                                                                                                                                                                                                       |
| II/0047 | Submission of the final report from study BO21223/GALLIUM listed as a category 3 study in the RMP. This is an open-label, international, multicenter, randomized, Phase III study to investigate the efficacy and safety of obinutuzumab administration at standard infusion rate plus chemotherapy followed by obinutuzumab maintenance therapy for responders (G-chemo arm) compared with rituximab plus chemotherapy followed by rituximab maintenance therapy for responders (R- chemo arm) in patients with previously untreated advanced indolent non-Hodgkin's lymphoma (iNHL). The RMP version 9.0 has also been submitted. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 21/07/2022 | 05/05/2023 | SmPC | Please refer to Scientific Discussion 'Gazyvaro-H-C-2799-II- 0047. For more information, please refer to the Summary of Product Characteristics.                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| IAIN/0049   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 06/05/2022   | 05/05/2023   | SmPC and PL   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|
| IB/0048     | B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 19/04/2022   | n/a          |               |
| IB/0046/G   | This was an application for a group of variations. B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.II.g.3 - Deletion of an approved change management protocol related to the finished product B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) | 10/02/2022   | n/a          |               |

<div style=\"page-break-after: always\"></div>

| B.II.d.2.d - Change in test product - Other changes (including replacement B.II.d.2.d - Change in test product - Other changes (including replacement B.I.e.3 - Deletion of an management protocol related B.I.d.1.c - Stability of AS period/storage period or to an approved stability B.I.b.1.b - Change in the and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS or material/intermediate B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS or material/intermediate B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS or material/intermediate B.I.b.2.e - Change in test   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where   |            |            |             |                                                                                                                                                                                                                                                                                             |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0044/G | This was an application for a group of variations. C.I.4 Update of sections 4.2, 4.8 and 5.1 of the SmPC in                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 16/09/2021 | 19/10/2021 | SmPC and PL | In patients with Follicular Lymphoma, obinutuzumab may be administered as a short (approximately 90 minutes) duration infusion after the first cycle of treatment, provided the patient did not experience Grade â‰¥ 3 infusion related reactions (IRRs) during the first cycle of treatment. |

<div style=\"page-break-after: always\"></div>

| order to include the as a short duration 90 minutes in patients (FL), based on the end efficacy data from the MO40597 (GAZELLE); the accordingly. The RMP version submitted. In addition, to update the list of local Package Leaflet. C.I.11.z Update of RMP version - change the due date CSR for Category 3 study Q4 2021 to Q1 2022; - remove important identified Assessment Report for 01Nov2018 to 30Oct2019 no.EMEA/H/C/PSUSA/00010279/201910); - correction of clinical cut-off exposure data from previously C.I.4 - Change(s) in the new quality, preclinical, data C.I.11.z - Introduction obligations and conditions   | administration of obinutuzumab infusion (SDI) of approximately with Follicular Lymphoma   | For more information, please refer to the Summary of Product Characteristics.   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| IA/0045             | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)                                                                  | 03/08/2021   | n/a   |                                  |                                                                                                                                                                          |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10279 /202010 | Periodic Safety Update EU Single assessment - obinutuzumab                                                                                                                                                                                                                           | 10/06/2021   | n/a   |                                  | PRAC Recommendation - maintenance                                                                                                                                        |
| IB/0042             | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                       | 08/01/2021   |       | SmPC, Annex II, Labelling and PL |                                                                                                                                                                          |
| PSUSA/10279 /201910 | Periodic Safety Update EU Single assessment - obinutuzumab                                                                                                                                                                                                                           | 14/05/2020   | n/a   |                                  | PRAC Recommendation - maintenance                                                                                                                                        |
| II/0038             | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                                                                                        | 17/04/2020   | n/a   |                                  |                                                                                                                                                                          |
| IB/0041/G           | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS | 14/04/2020   | n/a   |                                  |                                                                                                                                                                          |
| II/0036             | Update of sections 4.8 and 5.1 of the SmPC based on data from the final CSR of the pivotal study GA04753g/GO01297/GADOLIN to fulfill a Category 3                                                                                                                                    | 13/02/2020   |       | SmPC and PL                      | In the pivotal clinical study in patients with indolent Non- Hodgkin's lymphoma (GAO4753/GADOLIN), 97% (171 out of 176) of evaluable patients treated with Gazyvaro were |

<div style=\"page-break-after: always\"></div>

|           | PAM (MEA 006). The PL and RMP are updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                 |            |     | B-cell depleted at the end of the treatment period, and 97% (61 out of 63) remained depleted for more than 6 months from the last dose. Recovery of B-cells was observed within 12-18 months of follow-up in 11% (5 out of 46) of evaluable patients. At final analysis, the median observation time was 45.9 months (range: 0-100.9 months) for follicular lymphoma patients in the bendamustine arm and 57.3 months (range: 0.4-97.6 months) for patients in the Gazyvaro+bendamustine arm, representing an additional 25.6 months and 35.2 months of median follow-up in the two arms, respectively, since the primary analysis. Overall, the investigator assessed efficacy results were consistent with what was observed in the primary analysis. For more information please refer to the Summary of Product Characteristics.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0040   | B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits                                                                                                                                 | 07/02/2020 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0037   | B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol | 16/01/2020 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| IA/0035/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the                                                                                                                   | 02/10/2019 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|                     | finished product, including quality control sites (excluding manufacturer for batch release) B.I.a.z - Change in manufacture of the AS - Other variation                                                                                                                                       |            |            |             |                                                                                                                                                                                                                                                                        |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0034             | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required | 11/07/2019 | n/a        |             |                                                                                                                                                                                                                                                                        |
| PSUSA/10279 /201810 | Periodic Safety Update EU Single assessment - obinutuzumab                                                                                                                                                                                                                                     | 16/05/2019 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                      |
| R/0031              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                        | 31/01/2019 | 02/04/2019 | SmPC and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Gazyvaro in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| IG/1070             | B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State                                                                          | 04/03/2019 | n/a        |             |                                                                                                                                                                                                                                                                        |
| N/0030              | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                               | 09/08/2018 | 02/04/2019 | PL          |                                                                                                                                                                                                                                                                        |
| IB/0029             | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished                                                                                                                                                                                               | 25/07/2018 | n/a        |             |                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

|                     | product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |             |                                                                                                                                                                                                                                                       |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0028             | B.I.d.1.a.3 - Stability of AS - Change in the re-test period/storage period - Extension of storage period of a biological/immunological AS not in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 19/07/2018 | n/a        |             |                                                                                                                                                                                                                                                       |
| IB/0027             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 21/05/2018 | n/a        |             |                                                                                                                                                                                                                                                       |
| II/0023             | Update of section 4.8 and 5.1 of the SmPC in order to update the overall survival data based on final results from study BO21004/CLL11 listed as a category 3 study in the RMP; this is the pivotal study that evaluated the efficacy and safety of obinutuzumab as therapy for patients with previously untreated CLL with comorbidities; The RMP version 4.0 has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity format the listing of 'other side effects' and correct the term heart attack to heart failure in section 4 of the Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 17/05/2018 | 02/04/2019 | SmPC and PL | Section 4.8 and 5.1 of the SmPC were updated to amend the overall survival data based the final results from a study that evaluated the efficacy and safety of obinutuzumab as therapy for patients with previously untreated CLL with comorbidities. |
| PSUSA/10279 /201710 | Periodic Safety Update EU Single assessment - obinutuzumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 17/05/2018 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| IB/0026/G           | This was an application for a group of variations. B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS   | 30/04/2018   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                          |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0025             | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                                                                        | 14/04/2018   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                          |
| T/0024              | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                           | 15/03/2018   | 06/04/2018 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                          |
| IB/0021             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                        | 20/12/2017   | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                          |
| PSUSA/10279 /201704 | Periodic Safety Update EU Single assessment - obinutuzumab                                                                                                                                                                                                                                                    | 30/11/2017   | n/a        |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                        |
| II/0020             | Update of section 4.4 of the SmPC to revise the safety information on delayed hypersensitivity reactions based on a review of relevant cases by the Marketing authorisation holder (MAH). In addition, the MAH took the opportunity to introduce editorial changes to the SmPC and package leaflet.           | 26/10/2017   | 06/04/2018 | SmPC and PL            | Hypersensitivity reactions with immediate (e.g. anaphylaxis) and delayed onset (e.g. serum sickness) have been reported in patients treated with Gazyvaro. Hypersensitivity may be difficult to clinically distinguish from infusion related reactions. Hypersensitivity symptoms can occur after previous exposure and very rarely with the first infusion. If a hypersensitivity reaction is suspected |

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |                       | during or after an infusion, the infusion must be stopped and treatment permanently discontinued. Patients with known hypersensitivity to obinutuzumab must not be treated.   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0016             | Extension of Indication to include a new indication for Gazyvaro in combination with chemotherapy, followed by Gazyvaro maintenance therapy in patients achieving a response, for the treatment of patients with previously untreated advanced follicular lymphoma; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet and the RMP are updated in accordance. In addition, the due date for provision of the final clinical study report of study BO21223/GALLIUM listed in the Gazyvaro RMP as Category 3 has been updated. Furthermore, the Annex II is brought in line with the latest QRD template (version 10). In addition, clarification or editorial changes to the SmPC are proposed for accuracy and clarity. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 20/07/2017 | 18/09/2017 | SmPC, Annex II and PL | Please refer to the published Assessment Report Gazyvaro H-2799-II-016.                                                                                                       |
| PSUSA/10279 /201610 | Periodic Safety Update EU Single assessment - obinutuzumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 09/06/2017 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                             |
| II/0013/G           | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 15/12/2016 | n/a        |                       |                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

|                     | manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.g.1.a - Introduction of a new design space or extension of an approved design space for the finished product - One or more unit operations in the manuf. process of the FP including the resulting IPCs and/or test procedures                                             |            |     |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/10279 /201604 | Periodic Safety Update EU Single assessment - obinutuzumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 01/12/2016 | n/a | PRAC Recommendation - maintenance |
| IB/0015/G           | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place | 17/11/2016 | n/a |                                   |
| IB/0017             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                            | 10/11/2016 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0014             | B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation                                                                                                                                                                                                                                                                                                                                                                 | 20/10/2016   | n/a        |              |                                                                                |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|--------------|--------------------------------------------------------------------------------|
| IB/0012             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                       | 10/08/2016   | n/a        |              |                                                                                |
| II/0007             | Extension of indication to add the treatment of patients with follicular lymphoma based on the results of the pivotal study GAO4753g. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly. Furthermore, the MAH took the opportunity to make editorial changes to sections 4.4, 4.6, 5.3 and 6.6 of the SmPC. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 28/04/2016   | 13/06/2016 | SmPC and PL  | Please refer to the scientific discussion for Gazyvaro EMEA/H/C/002799/II/0007 |
| II/0010             | B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product                                                                                                                                                                                                                                                                              | 26/05/2016   | n/a        |              |                                                                                |
| PSUSA/10279 /201510 | Periodic Safety Update EU Single assessment - obinutuzumab                                                                                                                                                                                                                                                                                                                                                                                                                                          | 13/05/2016   | n/a        |              | PRAC Recommendation - maintenance                                              |
| II/0009             | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing                                                                                                                                                                                                                                                                                                                                                                                                          | 01/04/2016   | 20/05/2016 | Annex II and |                                                                                |

<div style=\"page-break-after: always\"></div>

|                     | authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required                                                                                                                                                                                                                                                                                                                                 |            |            | Labelling   |                                   |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| PSUSA/10279 /201504 | Periodic Safety Update EU Single assessment - obinutuzumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 06/11/2015 | n/a        |             | PRAC Recommendation - maintenance |
| IB/0005             | B.I.b.z - Change in control of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 22/07/2015 | n/a        |             |                                   |
| IG/0573             | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                                                                                                                                                                                     | 01/07/2015 | n/a        |             |                                   |
| II/0003             | Update of the SmPC sections 4.2 and 4.4 to revise the wording related to tumour lysis syndrome (TLS) in order to emphasize the importance of pre- medication and careful monitoring of patients at risk of TLS. In addition, text relating to batch number has been included in section 4.4 of the SmPC to improve the traceability of biological medicinal products. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 21/05/2015 | 20/05/2016 | SmPC and PL |                                   |
| PSUSA/10279 /201410 | Periodic Safety Update EU Single assessment - obinutuzumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 07/05/2015 | n/a        |             | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IG/0497   | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location   | 18/11/2014   | n/a   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|